GLOW1 and GLOW2 – Zenkuda also established superiority in ≥3 -step improvement in Diabetic Retinopathy Severity Score (DRSS) GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130); Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates 0% 13.7% 0% 5% 10% 15% 20% 25% Sham Zenkuda Proportion of patients with ≥3 -Step improvement in DRSS from Baseline to Week 48 p<0.0001 0% 5.6% 0% 5% 10% 15% 20% 25% Sham Zenkuda p=0.0058 GLOW1 GLOW2 6 Figure 4